Feature

Article

Pharmaceutical Executive

Pharmaceutical Executive: September 2024
Volume44
Issue 9

Pharmaceutical Executive: September 2024 Issue (PDF)

Click the title above for a link to open the Pharmaceutical Executive September 2024 issue in an interactive PDF format.

September 2024

Download Issue PDF
Articles in this issue
Pharmaceutical Executive: September 2024 Issue (PDF)
Pharmaceutical Executive: September 2024 Issue (PDF)
A Care Sea Change
A Care Sea Change
Jan van de Winkel: Antibody Ascension
Jan van de Winkel: Antibody Ascension
Biotech Performance Pivot May Be in the Offing
Biotech Performance Pivot May Be in the Offing
Delivery and Disruption: Navigating a Changing Care Terrain
Delivery and Disruption: Navigating a Changing Care Terrain
Outsourcing’s Evolution in the Pharma Industry
Outsourcing’s Evolution in the Pharma Industry

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Pharmaceutical Executive
Peter Rubin
Related Content
Stock.adobe.com
September 30th 2025

FDA Grants Approval for Kedrion Biopharma’s Primary Humoral Immunodeficiency Treatment Qivigy

Nicholas Jacobus
Pharmaceutical Executive
September 30th 2025

Pharmaceutical Executive Daily: September 29, 2025

Nicholas Jacobus
Stock.adobe.com
September 30th 2025

Novo Nordisk Resubmits Biologics License Application to FDA for Awiqli

Nicholas Jacobus
Pharmaceutical Executive
September 30th 2025

Pharmaceutical Executive Daily: September 26, 2025

Nicholas Jacobus
Stock.adobe.com
September 30th 2025

AbbVie Breaks Ground on Illinois API Manufacturing Site

Mike Hollan
Stock.adobe.com
September 30th 2025

Genmab Acquires Merus in $8 Billion Transaction Agreement Including Late-Stage Breakthrough Therapy Asset Petosemtamab

Nicholas Jacobus
© 2025 MJH Life Sciences

All rights reserved.